Nulojix
belatacept
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
What NULOJIX is and what it is used for
What you need to know before you use NULOJIX
How to use NULOJIX
Possible side effects
How to store NULOJIX
Contents of the pack and other information
NULOJIX contains the active substance belatacept which belongs to a group of medicines called immunosuppressants. These are medicines that reduce the activity of the immune system, the body's natural defences.
NULOJIX is used in adults to prevent the immune system from attacking your transplanted kidney and causing transplant rejection. It is used with other immunosuppressive medicines, including mycophenolic acid and corticosteroids.
exposure, you must not be treated with NULOJIX. EBV is the virus that causes glandular fever. If you have not been exposed to it, you are at a higher risk of getting a type of cancer called post- transplant lymphoproliferative disorder (PTLD). If you are not sure if you have been infected with the virus before, ask your doctor.
Post-transplant lymphoproliferative disorder
Treatment with NULOJIX increases the risk of getting a type of cancer called post-transplant lymphoproliferative disorder (PTLD). With NULOJIX treatment, this more often develops in the brain and can lead to death. People are at a higher risk of developing PTLD in the following cases:
If you have not been exposed to EBV prior to your transplant
If you are infected with a virus called cytomegalovirus (CMV)
If you have been given a therapy for treatment of acute rejection, such as antithymocyte globulin to reduce T-cells. T-cells are cells responsible for maintaining your body's ability to resist disease and infections. They may cause rejection of your transplanted kidney.
If you are not sure about any of these conditions, ask you doctor.
Serious infections
Serious infections can happen with NULOJIX treatment and can lead to death. NULOJIX weakens the body’s ability to fight infections. Serious infections can include
Tuberculosis
Cytomegalovirus (CMV), a virus that can cause serious tissue and blood infections
Shingles
Other herpes virus infections.
There have been reports of a rare type of brain infection called progressive multifocal leukoencephalopathy (PML) that have occurred in patients who have been given NULOJIX. PML often leads to severe disability or death.
Skin cancer
Limit your exposure to sunlight and ultraviolet (UV) light whilst using NULOJIX. Wear protective clothing and use a sunscreen with a high protection factor. People who use NULOJIX have a higher risk of getting certain other types of cancer, especially skin cancer.
Blood clotting in your transplanted kidney
Depending on the type of kidney transplant that you received, you may be at higher risk of blood clotting in your transplanted kidney.
Use in conversion from another type of immunosuppressive maintenance treatment
If your healthcare professional changes your maintenance treatment to a NULOJIX based immunosuppressive regimen, he/she may check your kidney function more often for a period of time after the change, to monitor for rejection.
Use in liver transplants
The use of NULOJIX is not recommended if you have had a liver transplant.
Use with other immunosuppressive medicines
Nulojix is normally given with steroids. Too rapid reduction of steroid intake can increase the risk that your body may reject the transplanted kidney. Please take the exact steroid dose as determined by your doctor.
NULOJIX has not been studied in children and adolescents under 18 years of age, therefore it is not recommended in this age group.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines. Ask your doctor or pharmacist for advice before taking any other medicine while using NULOJIX.
The use of live vaccines should be avoided with the use of NULOJIX. Tell your doctor if you need to have vaccinations. Your doctor will advise you what to do.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
If you become pregnant while using NULOJIX, tell your doctor.
Do not use NULOJIX if you are pregnant unless your doctor specifically recommends it. The effects of NULOJIX in pregnant women are not known. You must not get pregnant while using NULOJIX. If you are of child bearing potential, you should use effective contraception during treatment with NULOJIX and up to 8 weeks after the last dose of treatment since the potential risk to
embryonic/foetal development is unknown. Your doctor will advise you about using a reliable contraceptive.
You must stop breast-feeding if you are being treated with NULOJIX. It is not known whether belatacept, the active substance, passes into human milk.
Belatacept has a minor influence on the ability to drive and use machines. However you should not drive or operate any machines if you are feeling tired or unwell after receiving NULOJIX.
Tell your doctor if you are on a low-sodium (low-salt) diet before you are treated with NULOJIX. This medicine contains 0.55 mmol (or 13 mg) sodium per vial. This is equivalent to 0.64% of the recommended maximum daily dietary intake of sodium for an adult.
Treatment with NULOJIX will be prescribed and supervised by a specialist in kidney transplantation. NULOJIX will be given to you by a healthcare professional.
It will be given to you by infusion (as a "drip") into one of your veins over a period of about 30 minutes.
The recommended dose is based on your body weight (in kg) and will be calculated by a healthcare professional. The dose and treatment frequency is given below.
Initial Phase Dose
Day of transplantation, prior to implantation (Day 1)
Day 5, Day 14 and Day 28
End of Week 8 and Week 12 after transplantation
10 mg/kg
Maintenance Phase Dose
Every 4 weeks (± 3 days) starting at end of week 16 after transplantation 6 mg/kg
At the time of your kidney transplant you may be given NULOJIX in combination with other types of immunosuppressant medication to help prevent your body from rejecting your transplanted kidney.
Your doctor may decide to change your immunosuppressive treatment to a treatment with NULOJIX during the maintenance phase after your kidney transplant.
Information for medical and healthcare professionals on dose calculation, preparation and administration of NULOJIX is provided at the end of the leaflet.
If this happens, your doctor will monitor you for any signs or symptoms of side effects, and treat these symptoms if necessary.
It is very important for you to keep all appointments to receive NULOJIX. If you miss receiving NULOJIX when you are supposed to, ask your doctor when to schedule your next dose.
Your body may reject the transplanted kidney if you stop using NULOJIX. The decision to stop using NULOJIX should be discussed with your doctor and another therapy will generally be started.
If you stop treatment with NULOJIX for a long period of time, without taking any other medicines to prevent rejection, and then restart, it is not known if belatacept will have the same effect as before.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. However, NULOJIX can cause serious side effects that may need treatment.
Tell your family or caregiver about your treatment as you might get symptoms that you might not be aware of yourself.
Tell your doctor immediately if you or your family notice any symptoms listed below: Nervoussystemsymptoms may include memory lapse; speech and communication difficulties; a
change in your mood or behaviour; confusion or inability to control your muscles; weakness on one
side of the body; vision changes; or headache.
Infectionsymptoms may include fever; unexplained weight loss; swollen glands; cold symptoms such as a runny nose or sore throat; cough with sputum; blood in your sputum; earache; cuts or scrapes that are red; warm and oozing pus.
Kidneyorbladdersymptoms may include tenderness at the site of your transplanted kidney; difficulty passing urine; changes in the amount of urine you produce; blood in the urine; pain or burning on urination.
Gastrointestinalsymptoms may include pain on swallowing; painful mouth ulcers; white patches in the mouth or throat; upset stomach; stomach pain; vomiting; or diarrhoea.
Skinchanges may include unexpected bruising or bleeding; brown or black skin lesion with uneven borders, or one part of the lesion does not look like the other; a change in the size and colour of a mole; or a new skin lesion or bump.
Allergicreactions may include, but are not limited to, rash; reddened skin; hives; itching; lip swelling; tongue swelling; swelling of the face; swelling over entire body; chest pain; shortness of breath; wheezing; or dizziness..
Bladder or kidney infection, upper respiratory infection, CMV infection (can cause serious blood and tissue infections), fever, cough, bronchitis
Shortness of breath
Constipation, diarrhoea, nausea, vomiting, abdominal pain
High blood pressure, low blood pressure
Headache, difficulty sleeping, feeling nervous or anxious, swelling of the hands and feet
Joint pain, back pain, pain in the extremities
Pain when passing urine, blood in the urine Tests may show:
Low blood count or anaemia, low white blood cell count
Increased amounts of creatinine in your blood (blood test used to measure kidney function), increased amounts of protein in your urine
Changes in blood levels of different salts or electrolytes
Increased amounts of cholesterol and triglyceride (blood fats)
High levels of sugar in your blood
Cancer and non-cancerous growths of the skin
Dangerous decrease of blood pressure which, if untreated, may lead to collapse, coma and death
Stroke
Dead tissue because of stopped blood supply
Liver inflammation (cytolytic hepatitis)
Damage to the kidney
Fluid in the lungs, wheezing, chest pain or angina, enlarged heart muscle (bottom of the heart)
Infection of the blood or tissues, respiratory infections, pneumonia, flu, sinus inflammation, runny nose, sore throat, pain in the mouth/throat region, herpes virus infections, shingles and other viral infections, mouth sores, thrush, kidney infection, fungal skin infections,fungal infections of the nails and other fungal infections, skin infection, infection of soft tissues, wound infection, infection limited to one area, slow healing, bloody bruise, build up of lymph fluid around the transplanted kidney
Fast heart rate, slow heart rate, abnormal and irregular heart beat, weak heart
Diabetes
Dehydration
Inflammation of the stomach and intestines, usually caused by a virus
Upset stomach
Unusual sensation of pins and needles, numbness or weakness of the arms and legs
Rash, itching
Muscle pain, muscle weakness, bone pain, joint swelling, abnormal cartilage between bones of the spine, sudden inability to bend joint, muscle spasms, arthritis
Blockage of kidney blood vessels, enlarged kidney due to blockage of urine flow out of the
kidney, backflow of urine from the bladder into the kidney tubes, inability to hold urine, incomplete emptying of the bladder, urinating at night, sugar in the urine
Increase in body weight, decrease in body weight
Cataract, increased blood congestion in the eye, blurred vision
Shaking or tremors, dizziness, fainting or passing out, ear pain, buzzing, ringing or other persistent noise in the ears
Acne, hair loss, abnormal change to the skin, excessive sweating, night sweats
Weakness/gap in abdominal muscles and out pouching of skin over healed incision, hernia on the stomach wall
Depression, fatigue, feeling of tiredness, drowsiness, or lack of energy, general feeling of being unwell, difficulty breathing when laying down, nose bleeding
Typical appearance of a person with high levels of steroids, such as moon face, hump back, upper body obesity
Abnormal collection of fluid Tests may show:
Low platelet counts in your blood, too many white blood cells, too many red blood cells
Changes in blood levels of carbon dioxide, fluid retention, low protein in the blood
Abnormal liver function tests, blood parathyroid hormone increased
Increased protein (c-reactive protein) in blood indicating inflammation
A decrease of antibodies (proteins that fight infection) in your blood
Lung cancer, rectal cancer, breast cancer, a form of cancer in the bones, musles, or fat tissue, tumor of the skin and intestinal tract caused by a herpes virus and seen in patients with a weakened immune system, prostate cancer, cancer of the cervix, throat cancer, cancer of the lymph nodes, cancer of the bone marrow, cancer of the kidney, kidney tubes, or bladder
Fungal infection of brain, inflammation of the brain, serious brain infection called PML (progressive multifocal leukoencephalopathy)
Abnormal swelling of the brain, increased pressure inside the skull and brain, seizure, weakness causing loss of movement on one side of the body, loss of the covering around nerves, inability of muscles to move in the face
Any disease of the brain causing headache, fever, hallucinations, confusion, abnormal speech and
body movement
Poor blood flow to the heart, blocked heart beats, abnormal aorta heart valve, abnormal rapid heart rate
Sudden problems with breathing leading to lung damage, increased blood pressure in the lungs,
inflammation of the lungs, coughing up blood, abnormality of lungs and air tubes delivering air in
and out of lungs, fluid in the sac around the lungs, breathing that stops temporarily during sleep, abnormal speaking sound
Genital herpes
Inflammation of the colon (large bowel) caused by the cytomegalovirus, inflammation of the pancreas, ulcer in the stomach, small intestines, or large intestine, blockage of the small intestine, black, tar-like stools, rectal bleeding, abnormal colour of the stool
Bacterial infections, inflammation or infection of the inner layer of the heart, tuberculosis, bone
infection, inflammation of the lymph nodes, chronic dilation of the airways in the lungs with frequent lung infections
Infection with the strongyloides worm, diarrheal infection with Giardia parasite
Kidney disease that is caused by a virus (polyomavirus-associated nephropathy), inflammation of the kidneys, scarring of the kidneys, shrinkage of the small tubes in the kidney, inflammation of the bladder with bleeding
Blood clotting in kidney artery
Guillian-Barré syndrome (a condition that causes muscle weakness or paralysis)
EBV (Epstein-Barr virus) lymphoproliferative disease
Blood clotting in veins, inflamed veins, periodic leg cramps
Abnormal arteries, scarring of the arteries, clotting in the arteries, narrowing of the arteries, temporary redness of the face/skin, swelling of the face
Stones in the gallbladder, fluid filled pocket in the liver, fatty liver
Skin disease with thickened patches of red skin, often with silvery scales, abnormal hair growth, excessive hair breakage, nails breaking, ulcer on the penis
Abnormal balance of minerals in the body causing bone problems, bone inflammation, abnormal weakening of the bone leading to bone problems, inflammation of the lining of the joints, rare bone condition
Inflammation of the testicles, an abnormally prolonged penile erection, abnormal cervical cells, breast mass, pain in the testes, ulcer in the female genital area, thinned vaginal walls, infertility or inability to become pregnant, swelling of the scrotum
Seasonal allergy
Poor appetite, loss of taste, decreased hearing
Abnormal dreams, mood swings, abnormal lack of ability to focus and sit still, difficulty understanding or thinking, poor memory, migraine, irritability
Numbness or weakness from poorly controlled diabetes, changes in the foot from diabetes, inability to keep legs still
Swelling of back of the eye causing changes in sight, eye inflamed, uncomfortable/increased sensitivity to light, swelling of the eyelid
Cracking of the corner of the mouth, swollen gums, salivary gland pain
Increased sexual desire
Burning sensation
Reaction to an infusion, scare tissue, inflammation, return of disease, feeling hot, ulcer
Not making enough urine
Failure of transplanted organ to work, problems during or after a transfusion, separation of the wound edges before it heals, broken bone, complete tear or separation of tendon, low blood pressure during or after a procedure, high blood pressure during or after a procedure, bruise/collection of blood within the soft tissues after a procedure, pain related to a procedure, headache related to a procedure, bruise of the soft tissue
Tests may show:
Dangerously low red blood cells, dangerously lowered white cell counts, destruction of red blood cells, blood clotting problems, acid in the blood from diabetes, lack of acid in the blood
Improper production of hormones by the adrenal glands
Low vitamin D levels
Pancreatic enzymes in the blood increased, troponin levels in the blood increased, prostate- specific antigen (PSA) increased, high uric acid levels in the blood, CD-4 lymphocyte cell counts decreased, low blood sugar
If any of the side effects gets serious, please tell your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via thenationalreporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the vial label and carton after EXP. The expiry date refers to the last day of that month.
This medicine will be stored in the healthcare facility where it is administered. Store in a refrigerator (2 °C – 8 °C).
Store in the original package in order to protect from light.
After reconstitution, the reconstituted solution should be transferred from the vial to the infusion bag or bottle immediately.
After dilution, and from a microbiological point of view, the product should be used immediately. If not used immediately, the solution for infusion may be stored in a refrigerator (2 °C – 8 °C) for up to 24 hours. The solution for infusion may be stored for a maximum of 4 hours of the total 24 hours below 25 °C. Do not freeze.
The NULOJIX infusion must be completed within 24 hours of reconstitution of the powder.
Do not use NULOJIX if you notice any particles or discolouration in the reconstituted or diluted solution.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is belatacept. Each vial contains 250 mg of belatacept. After reconstitution, each ml of concentrate contains 25 mg of belatacept.
The other ingredients are sodium chloride, sodium dihydrogen phosphate monohydrate, sucrose,
sodium hydroxide (for pH adjustment) and hydrochloric acid (for pH adjustment). (See section 2)
NULOJIX powder for concentrate for solution for infusion (powder for concentrate) is a white to off- white powder that can appear solid or broken into pieces.
Each vial contains 250 mg belatacept.
Packs of either 1 glass vial and 1 syringe or 2 glass vials and 2 syringes. Not all pack sizes may be marketed.
Marketing Authorisation Holder:
Bristol-Myers Squibb Pharma EEIG Plaza 254
Blanchardstown Corporate Park 2
Dublin 15, D15 T867 Ireland
Manufacturer:
Swords Laboratories Unlimited Company T/A Bristol-Myers Squibb Cruiserath Biologics Cruiserath Road, Mulhuddart
Dublin 15, D15 H6EF Ireland
-------------------------------------------------------------------------------------------------------------------------
Use aseptic technique to make up the vials and dilute the solution for administration.
Use the silicone-free disposable syringe provided to make up the vials and to add the solution to the infusion. This will avoid aggregate formation.
Do not shake the vials. This will avoid foam formation.
The solution for infusion is to be used in conjunction with a sterile, non-pyrogenic, low protein binding filter (pore size of 0.2 µm to 1.2 µm).
Calculate the dose and number of NULOJIX vials required. Each NULOJIX vial provides 250 mg of belatacept.
Total dose of belatacept in mg equals the patient weight in kg times the belatacept dose in mg/kg (6 or 10 mg/kg, see section 3)
Dose modification of NULOJIX is not recommended for a change in body weight of less than 10%.
Number of vials required equals the belatacept dose in mg divided by 250 rounded up to the next full number of vials.
Make up each vial with 10.5 ml reconstitution solution.
Volume of the reconstituted solution required (ml) equals total belatacept dose in mg divided by 25.
Using aseptic technique, make up each vial with 10.5 ml of one of the following solvents (sterile water for injections, sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose solution for injection), using the co-packed disposable syringe (necessary to avoid aggregate formation) and an 18- 21 gauge needle. Syringes are marked in units of 0.5 ml; therefore, the calculated dose should be rounded to the nearest 0.5 ml.
Remove the flip off seal from the vial and wipe the top with an alcohol swab. Insert the syringe needle into the vial through the centre of the rubber stopper. Direct the stream of fluid to the glass wall of the vial and not into the powder. Remove the syringe and needle after 10.5 ml of reconstitution fluid has been added to the vial.
To minimise foam formation, gently swirl and invert the vial for at least 30 seconds or until the powder is completely dissolved. Do not shake. Although some foam may remain on the surface of the reconstituted solution, a sufficient excess of belatacept is included in each vial to account for withdrawal losses. Thus, 10 ml of a 25 mg/ml belatacept solution can be withdrawn from each vial.
The reconstituted solution should be clear to slightly opalescent and colourless to pale yellow. Do not use if opaque particles, discolouration or other foreign particles are present. It is recommended to transfer the reconstituted solution from the vial to the infusion bag or bottle immediately.
After reconstitution, dilute the product to 100 ml with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose solution for injection. From a 100 ml infusion bag or bottle (typically, an infusion volume of 100 ml will be appropriate for most patients and doses, but total infusion volume ranging from 50 ml to 250 ml may be used), withdraw a volume of sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose solution for injection equal to the volume (ml equals total dose
in mg divided by 25) of the reconstituted NULOJIX solution required to provide the dose and discard it. Slowly add the required amount of reconstituted NULOJIX solution from each vial to the infusion bag or bottle using the same disposable syringe used for reconstitution of the powder. Gently mix the infusion container. The concentration of belatacept in the infusion should be between 2 mg and 10 mg belatacept per ml solution.
Any unused portion in the vials must be discarded in accordance with local requirements.
When reconstitution and dilution are performed under aseptic conditions, the NULOJIX infusion should be started immediately or must be completed within 24 hours of reconstitution of the powder.
If not used immediately, the solution for infusion may be stored in the refrigerator (2 °C – 8 °C) for up
to 24 hours. Do not freeze. The solution for infusion may be stored for a maximum of 4 hours of the total 24 hours below 25 °C. Infusion must be completed within 24 hours of reconstitution of the powder. Prior to administration, the solution for infusion should be inspected visually for particulate matter or discolouration. Discard the solution if any particulate matter or discolouration is observed. The entire, fully diluted infusion should be administered over a period of 30 minutes and must be administered with an infusion set and a sterile, non-pyrogenic, low protein binding filter (pore size of
0.2 μm to 1.2 μm). Following administration, it is recommended that the intravenous line be flushed with infusion fluid to ensure administration of the complete dose.
NULOJIX should not be infused concomitantly in the same intravenous line with other agents. No physical or biochemical compatibility studies have been conducted to evaluate the coadministration of NULOJIX with other agents.
Do not store any unused portion of the solution for infusion for reuse.
Any unused product or waste material should be disposed of in accordance with local requirements.